Back to Search
Start Over
9-12 months short treatment for patients with MDR-TB increases treatment success in Kyrgyzstan.
- Source :
-
Journal of infection in developing countries [J Infect Dev Ctries] 2021 Sep 29; Vol. 15 (9.1), pp. 66S-74S. Date of Electronic Publication: 2021 Sep 29. - Publication Year :
- 2021
-
Abstract
- Introduction: MDR/RR-TB is a growing problem in Kyrgyzstan. In 2005, the country introduced standard or individualized treatment for 20-24 months. Because of poor treatment outcomes, in 2017 a short treatment with strict eligibility criteria was introduced. The aim of this study was to compare characteristics and treatment outcomes of MDR/RR-TB patients receiving short (9-12 months) treatment in 2017 with those receiving standard or individualized (20-24 months) treatment in 2016/2017.<br />Methodology: A comparative cohort study using routine programmatic data. Characteristics, sputum culture conversion and treatment outcomes were compared between those on short treatment with those on standard/individualized treatment using the chi-square test, crude and adjusted risk ratios (RR and aRR).<br />Results: The study included 274, 82 and 132 patients on standard, individualized and short treatment, respectively. There were more females, fewer migrants/homeless and unemployed and more new TB patients on short treatment compared with the other two groups. A favorable outcome (cure and treatment completed) was significantly higher in short treatment patients (83%) compared with those on standard (50%) or individualized (59%) treatment (p < 0.001). There was higher 1-month sputum culture conversion with short treatment (35%) compared with the other two groups (19% and 24%, p < 0.05). Short treatment (aRR 1.6, 1.4-1.8), female gender (aRR 1.2, 1.1-1.4), not being homeless (aRR 12.9, 4.5-17.3) and having new TB (aRR 1.3, 1.0-1.5) were independently associated with a favorable outcome.<br />Conclusions: The treatment success was higher in selected MDR-TB patients given short treatment in Kyrgyzstan: this regimen should be scaled-up to all MDR-TB patients.<br />Competing Interests: No Conflict of Interest is declared<br /> (Copyright (c) 2021 Elena Zhdanova, Olga Goncharova, Hayk Davtyan, Sevak Alaverdyan, Aelita Sargsyan, Anthony D Harries, Bolot Maykanaev.)
Details
- Language :
- English
- ISSN :
- 1972-2680
- Volume :
- 15
- Issue :
- 9.1
- Database :
- MEDLINE
- Journal :
- Journal of infection in developing countries
- Publication Type :
- Academic Journal
- Accession number :
- 34609962
- Full Text :
- https://doi.org/10.3855/jidc.13757